A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia

Mathilde Berger; Mona Amini-Adlé; Laura Crumbach; Etienne Paubelle; Stéphane Dalle

doi:10.1016/j.ejca.2019.02.006

A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia

Eur J Cancer. 2019 May:112:94-97. doi: 10.1016/j.ejca.2019.02.006. Epub 2019 Apr 4.

Authors

Mathilde Berger¹, Mona Amini-Adlé¹, Laura Crumbach¹, Etienne Paubelle², Stéphane Dalle³

Affiliations

¹ Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service de dermatologie, Pierre-Bénite, France.
² Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'hématologie, Pierre-Bénite France.
³ Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service de dermatologie, Pierre-Bénite, France. Electronic address: stephane.dalle@chu-lyon.fr.

PMID: 30954716
DOI: 10.1016/j.ejca.2019.02.006

No abstract available

Keywords: Immune checkpoint blocking agents; Immune related adverse events; Immunotherapy; Melanoma; PD1-inhibitor; Pure red cell aplasia; Thrombocytopaenia.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / adverse effects*
Antineoplastic Agents, Immunological / therapeutic use
Female
Humans
Immunotherapy / methods
Melanoma / immunology
Melanoma / therapy*
Middle Aged
Purpura, Thrombocytopenic, Idiopathic / chemically induced*
Red-Cell Aplasia, Pure / immunology*

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
pembrolizumab